Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...

Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...